Cargando…

Long term treatment with ataluren—the Swedish experience

INTRODUCTION: Ataluren is a relatively new treatment for male patients with Duchenne muscular dystrophy (DMD) due to a premature stop codon. Long-term longitudinal data as well as efficacy data on non-ambulant patients are still lacking. Here we present the results from a long-term follow-up study o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michael, Eva, Sofou, Kalliopi, Wahlgren, Lisa, Kroksmark, Anna-Karin, Tulinius, Már
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485550/ https://www.ncbi.nlm.nih.gov/pubmed/34592975 http://dx.doi.org/10.1186/s12891-021-04700-z

Ejemplares similares

One in five patients with Duchenne muscular dystrophy dies from other causes than cardiac or respiratory failure
por: Wahlgren, Lisa, et al.
Publicado: (2021)

NFL is a marker of treatment response in children with SMA treated with nusinersen
por: Olsson, Bob, et al.
Publicado: (2019)

Ataluren treatment of patients with nonsense mutation dystrophinopathy
por: Bushby, Katharine, et al.
Publicado: (2014)

Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients
por: McDonald, Craig M, et al.
Publicado: (2021)

Treatment with Ataluren for Duchene Muscular Dystrophy
por: Morkous, Sameh S.
Publicado: (2020)

Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study
por: Mercuri, Eugenio, et al.
Publicado: (2020)

Effect of Ataluren on dystrophin mutations
por: Berger, Joachim, et al.
Publicado: (2020)

Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study
por: Goemans, Nathalie M., et al.
Publicado: (2016)

Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy
por: Namgoong, John Hyun, et al.
Publicado: (2016)

Caffeine boosts Ataluren's readthrough activity
por: Lentini, Laura, et al.
Publicado: (2019)

Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects
por: Kong, Ronald, et al.
Publicado: (2019)

Ataluren for the Treatment of Usher Syndrome 2A Caused by Nonsense Mutations
por: Samanta, Ananya, et al.
Publicado: (2019)

Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis
por: Mercuri, Eugenio, et al.
Publicado: (2023)

Ataluren—Promising Therapeutic Premature Termination Codon Readthrough Frontrunner
por: Michorowska, Sylwia
Publicado: (2021)

Formulation and Stability of Ataluren Eye Drop Oily Solution for Aniridia
por: Djayet, Celia, et al.
Publicado: (2020)

Correction to: Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis
por: Mercuri, Eugenio, et al.
Publicado: (2023)

Whole exome sequencing reveals mutations in NARS2 and PARS2, encoding the mitochondrial asparaginyl-tRNA synthetase and prolyl-tRNA synthetase, in patients with Alpers syndrome
por: Sofou, Kalliopi, et al.
Publicado: (2015)

Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms
por: Ng, Martin Y., et al.
Publicado: (2021)

Ketogenic diet in pyruvate dehydrogenase complex deficiency: short- and long-term outcomes
por: Sofou, Kalliopi, et al.
Publicado: (2017)

Early treatment with Ataluren of a 2-year-old boy with nonsense mutation Duchenne dystrophy
por: Bitetti, Ilaria, et al.
Publicado: (2021)

Ataluren suppresses a premature termination codon in an MPS I-H mouse
por: Wang, Dan, et al.
Publicado: (2022)

In vitro metabolism, reaction phenotyping, enzyme kinetics, CYP inhibition and induction potential of ataluren
por: Kong, Ronald, et al.
Publicado: (2020)

Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up
por: Dori, Amir, et al.
Publicado: (2021)

Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up
por: Dori, Amir, et al.
Publicado: (2022)

Ataluren for drug‐resistant epilepsy in nonsense variant‐mediated Dravet syndrome and CDKL5 deficiency disorder
por: Devinsky, Orrin, et al.
Publicado: (2021)

Aminoglycosides, but not PTC124 (Ataluren), rescue nonsense mutations in the leptin receptor and in luciferase reporter genes
por: Bolze, Florian, et al.
Publicado: (2017)

Blood-Based Biomarkers and Long-term Risk of Frailty—Experience From the Swedish AMORIS Cohort
por: Wennberg, Alexandra M, et al.
Publicado: (2021)

A multicenter study on Leigh syndrome: disease course and predictors of survival
por: Sofou, Kalliopi, et al.
Publicado: (2014)

Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
por: Finkel, Richard S., et al.
Publicado: (2013)

Ataluren binds to multiple protein synthesis apparatus sites and competitively inhibits release factor-dependent termination
por: Huang, Shijie, et al.
Publicado: (2022)

Parental experiences of having a child with CLN3 disease (juvenile Batten disease) and how these experiences relate to family resilience
por: Krantz, Mattias, et al.
Publicado: (2022)

One-year follow up of three Italian patients with Duchenne muscular dystrophy treated with ataluren: is earlier better?
por: Ruggiero, Lucia, et al.
Publicado: (2018)

Long-Term Effect of Bariatric Surgery on Liver Enzymes in the Swedish Obese Subjects (SOS) Study
por: Burza, Maria Antonella, et al.
Publicado: (2013)

A Lack of Premature Termination Codon Read-Through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays
por: McElroy, Stuart P., et al.
Publicado: (2013)

Good response to the late treatment with ataluren in a boy with Duchenne muscular dystrophy: could the previous mild course of the disease have affected the outcome?
por: Pasca, Ludovica, et al.
Publicado: (2022)

Off-Label Use of Ataluren in Four Non-ambulatory Patients With Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength
por: Ebrahimi-Fakhari, Daniel, et al.
Publicado: (2018)

Long-term Follow-up of 84 Patients With Giant Prolactinomas—A Swedish Nationwide Study
por: Himonakos, Christos, et al.
Publicado: (2023)

Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients
por: Bywall, Karin Schölin, et al.
Publicado: (2020)

Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: Lessons learned from the first ataluren phase 3 study
por: Tiddens, Harm A. W. M., et al.
Publicado: (2020)

Corrigendum: Off-Label Use of Ataluren in Four Non-ambulatory Patients With Duchenne Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle Strength
por: Ebrahimi-Fakhari, Daniel, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g0knbr0tvbuekjhrb75ranke9d